Active substanceThiethylperazineThiethylperazine
Similar drugsTo uncover
  • Torekan
    pills inwards 
  • Torekan
    suppositories rect. 
  • Torekan
    solution w / m in / in 
  • Dosage form: & nbspcoated tablets
    Composition:
    1 tablet contains:
    CORE
    Active substance:
    Tethylpiperazine dimaleate 10.300 mg
    (equivalent to 6.5 mg of thiethylperazine)
    Excipients:
    Lactose Monohydrate 68,700 mg
    Corn starch 14,000 mg
    Talc 2,000 mg
    Stearic acid 2,000 mg
    Gelatin 3,000 mg
    SHELL
    Sucrose 38,045 mg
    Acacia gum 0,634 mg
    Talc 20,095 mg
    Titanium dioxide 1.236 mg
    Capol 600 * 0,450 mg
    * Capol 600 (beeswax white, carnauba wax, shellac) is not included in the final mass of tablets.

    Description:
    Round biconvex tablets, covered with a coat of white or almost white. A specific odor is allowed.

    Pharmacotherapeutic group:antiemetic
    ATX: & nbsp

    R.06.A.D.   Phenothiazine derivatives

    R.06.A.D.03   Thiethylperazine

    Pharmacodynamics:Antiemetic means of central action (piperazine derivative of phenothiazine), blocks H1 - histamine receptors and dopamine receptors in nigrostriral pathways, practically has no antipsychotic effect. It has alpha-adrenoblocking and m-holinoblocking action. It acts on the chemoreceptor trigeminal zone and the vomiting center.Eliminates dizziness, affecting the focal points in the reticular formation. The effect develops rapidly, usually after the first use of ethylamprazine.
    Pharmacokinetics:
    Suction
    Absorption is high.
    The maximum concentration is achieved after 2 to 4 hours after ingestion.
    Distribution
    Lipophilin and strongly binds to blood plasma proteins (over 85%). It accumulates in organs with good blood flow and easily penetrates the placenta. The volume of distribution is 2.7 l / kg. Not output by dialysis.
    Metabolism and excretion
    Metabolized mainly in the liver. Only 3% is excreted by the kidneys unchanged. The half-life (T1 / 2) is approximately 12 hours.
    Indications:
    Nausea and vomiting after surgery, with craniocerebral trauma, chemoradiotherapy, with diseases of the gastrointestinal tract, liver and bile ducts, with intolerance of medicines, sea and air sickness, dizziness of central and vestibular origin (concussion , atherosclerosis, vestibular and labyrinthine disorders, Meniere's disease).

    Contraindications:
    Hypersensitivity to thiethylperazine,phenothiazines or any of the adjuvant components of the drug, severe CNS depression and / or consciousness disorder, clinically significant hypotension, angle-closure glaucoma (acute attack), renal and / or hepatic insufficiency, blood diseases, bronchial asthma, prostatic hyperplasia, Parkinson's disease and / or parkinsonism,
    pregnancy, breastfeeding period, Reye syndrome, children under 15 years of age (risk of extrapyramidal disorders), sugar / isomaltase deficiency, lactose intolerance, glucose-galactose malabsorption syndrome, prolactinoma, concomitant use with bromocriptine.

    Pregnancy and lactation:
    Data on the use of thiethylperazine in pregnant women are absent. Torekan should not be used during pregnancy, except when the benefits to the mother exceed the potential risk to the fetus.
    Data on the isolation of thiethylperazine with breast milk are not available, therefore, if you need to use the drug Torekan during lactation, breastfeeding should be canceled

    Dosing and Administration:
    Inside, squeezed a small amount of liquid. *
    Adults and children over 15 years: the recommended dose - 1 tablet (6.5 mg) 1-3 times a day.
    Renal and / or hepatic impairment
    The dosage regimen in patients with renal and / or hepatic impairment is not precisely defined, tem'ne less in these patients is recommended lowering the dose to 1 tablet 1 time a day.
    The duration of treatment depends on the course of the disease.
    Torekan is usually prescribed for one day. If necessary, treatment can be continued up to several days or weeks.
    Elderly patients
    Treatment of patients older than 75 years should not continue for more than 2 months because of the risk 1 of involuntary movements (tardive dyskinesia).

    Side effects:
    Classification of the incidence of adverse events (WHO):
    Often ; > 1/10 .
    often . from> 1/100 to <1/10
    infrequently from> 1/1000 to <1/100
    rarely, from> 1/10000 to <1/1000
    very rarely from <1/10000, including individual messages. ,
    From the cardiovascular system:
    - rarely: peripheral edema, orthostatic hypotension; very rarely: tachycardia, lowering blood pressure, changing the T wave on the ECG;
    From the nervous system:
    infrequently: headache, dizziness, drowsiness, restlessness; rarely: seizures or extrapyramidal disorders (torticollis, opisthotonus,
    oculogic crisis (spasm of eyesight), rigidity of muscles, grimaces) - more often in children and adolescents; in elderly patients after prolonged use of the drug may develop tardive dyskinesia (involuntary movements);
    very rarely: neuralgia of the trigeminal nerve, paradoxical reactions ("nightmarish" dreams, unusual agitation, nervousness, irritability);
    From the sense organs:
    rarely: clouding of the lens, miosis, decreased vision, hyperpigmentation of the retina; - On the part of the digestive system:
    rarely: anorexia, dryness of the oral mucosa, constipation;
    very often: cholestatic jaundice, paralytic intestinal obstruction, impaired liver function;
    From the endocrine system:
    rarely: gynecomastia, menstrual disorders, changes in libido, increase, body weight;
    From the skin:
    very rarely: exfoliative dermatitis, photosensitivity;
    Allergic reactions:
    very rarely: allergic reactions;
    Laboratory indicators:
    very rarely: thrombocytopenia, leukopenia, 'agranulocytosis,' 'aplastic' anemia // pancytopenia;
    Other:
    very rarely: impaired renal function.

    Overdose:
    Symptoms: dryness of the oral mucosa, dizziness, confusion, postural hypotension, collapse.
    In severe intoxication - coma, 'areflexia, tachycardia and respiratory depression, acute dystonia, convulsions, agitation.
    Treatment: symptomatic, there is no specific antidote. Recommended gastric lavage, the use of activated charcoal. In other cases, vital / important functions should be monitored. For the treatment of dystonic reactions, anti-Parkinsonics are used, for the treatment of seizures, benzodiazepines,
    to fight with circulatory insufficiency - plasma substitutes and vasopressors (apply epinephrine should not be used norepinephrine).
    Hemodialysis is ineffective.

    Interaction:
    Thiethylperazine can enhance the action of CNS depressants, including tranquilizers, opioids, anesthetics, hypnotics and ethanol.
    Tricyclic antidepressants and thiethylperazine can enhance the action and toxicity of each other.
    Thiethylperazine can 'reduce the effectiveness of epinephrine, therefore, epinephrine should not be used to treat arterial hypotension caused by thiethylperazine., 'Simultaneous' application of thiethylperazine and bromocriptine reduces the inhibitory effect of bromocriptine on the secretion of prolactin. Therefore, the use of thiethylperazine 'is not recommended for patients with prolactinoma receiving bromocriptine. The simultaneous use of monoamine oxidase (MAO) and-phenothiazine inhibitors can lead to an increase in undesirable effects of MAO inhibitors (hypotension, respiratory depression and CNS). Phenothiazines can enhance the undesirable effects of procarbazine.
    Special instructions:
    Like other antiemetics, Torekan can mask the symptoms of certain gastrointestinal and CNS diseases, as well as the toxic effects of other drugs.
    In connection with the additive hypotensive effect of Torekan, it should be used with caution, patients with spinal anesthesia and. patients, who simultaneously take beta-blockers.
    When using Torekan in pregnant women with preeclampsia, a significant reduction in blood pressure is possible.
    Torekan should be used with caution in patients with dyskinesia - and moderate or severe impairment of liver function.
    With the development of malignant neuroleptic syndrome (hyperpyrexia, muscle rigidity, altered mental state, signs of autonomic nervous disorder, system), Torekan should be stopped immediately. The drug Torekan can cause neurologic disorders (the risk of involuntary movements).
    The drug Torekan contains lactose, therefore it is contraindicated in patients with a deficiency of sugar / isomaltase, intolerance to lactose and glucose-galactose malabsorption syndrome.

    Effect on the ability to drive transp. cf. and fur:drug Torekan has a pronounced effect on psychomotor reactions, and therefore, during the period of treatment should abandon the management of vehicles and work with complex technical devices that require increased concentration and speed of psychomotor reactions
    Form release / dosage:
    Coated tablets, 6.5 mg.

    Packaging:
    50 tablets in a vial of dark glass with a plastic lid made of polyethylene. Free space in the bottle is filled with cotton:
    1 bottle is placed in a pack of cardboard along with instructions for use.
    Storage conditions:
    At a temperature of no higher than 25 ° C.,
    Keep out of the reach of children.

    Shelf life:
    5 years.
    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N012413 / 01
    Date of registration:01.12.20011
    The owner of the registration certificate:KRKA, dd, Novo mesto, AOKRKA, dd, Novo mesto, AO
    Manufacturer: & nbsp
    Information update date: & nbsp12.09.2015
    Illustrated instructions
      Instructions
      Up